Rethinking Alzheimer's: novel miRNAs illuminate a disease beyond the brain

J S Novotný1,2, M Čarná1, E B Dammer3

  • 1Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacký University Olomouc, Olomouc, Czech Republic.

Molecular Psychiatry
|February 13, 2026
PubMed

Insights

Alzheimer's disease (AD) involves widespread changes in circulating microRNAs (miRNAs), including novel ones. These findings suggest AD may be a systemic disorder, not just brain-specific, opening new avenues for biomarkers and therapies.

Area of Science:

  • Neuroscience
  • Genetics
  • Biochemistry

Background:

  • Alzheimer's disease (AD) presents significant global challenges, yet its pathogenesis remains incompletely understood.
  • Emerging evidence indicates complex alterations in circulating microRNAs (miRNAs) in AD patients.

Purpose of the Study:

  • To comprehensively characterize the changes in miRNAs associated with Alzheimer's disease using meta-analysis.
  • To identify novel miRNAs and biological pathways implicated in AD pathogenesis.

Main Methods:

  • Conducted two meta-analytical approaches on data from 22 studies, involving 4186 individuals.
  • Identified a comprehensive set of 2895 miRNAs and analyzed those with significant changes in AD.

Main Results:

  • Identified 194 miRNAs with widespread changes in AD, including 32 novel miRNAs not previously linked to the disease.
  • Analysis of miRNA targets revealed poorly understood biological pathways, including interleukin signaling, Toll receptor signaling, p38 MAPK, and insulin/IGF pathways.
  • Several identified "AD miRNAs" were found outside the brain, suggesting a systemic role.

Conclusions:

  • Alzheimer's disease may be a systemic disorder rather than exclusively brain-specific.
  • Findings expand the understanding of miRNA involvement in AD pathogenesis and highlight potential systemic pathways.
  • Results provide a foundation for developing novel AD biomarkers and miRNA-targeted therapies.

Related Concept Videos

Amyloid Fibrils03:03

Amyloid Fibrils

Amyloid fibrils are aggregates of misfolded proteins.  Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils. 
Amyloid deposits were observed as early as 1639 in the liver and the spleen.   In 1854, Rudolph Virchow performed iodine staining, normally used to...
siRNA - Small Interfering RNAs02:30

siRNA - Small Interfering RNAs

Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the ATP-dependent...
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...